Trends & Analysis Posts
Trends & Analysis
Redica Responds: What are Common Laboratory Inspection Findings?
Redica Systems
May 1, 2023
Conference Spotlight
Is Raw FDA Data Skewing Your Analyses?
Redica Systems
March 23, 2023
Trends & Analysis
Instant Download: Insights on Quality from FDA Leaders
Redica Systems
November 8, 2022
Trends & Analysis
PAIs and 483 Issuance Risk: The Trends Are Not What They Seem
Redica Systems
September 8, 2022
Trends & Analysis
Instant Download | Analysis of 2021 U.S. FDA 483 GMP Observations
Barbara W. Unger
May 3, 2022
Trends & Analysis
Instant Download | Yes, Warehouses Must Comply with Relevant GMPs
Barbara W. Unger
March 8, 2022
Trends & Analysis
Instant Download | FY2020 and FY2021 Drug GMP Warning Letter Analysis
Barbara W. Unger
February 11, 2022
Trends & Analysis
Instant Download | Analysis of COVID-19 Vaccine and Drug 483s
Barbara W. Unger
January 25, 2022
Trends & Analysis
How Small Pharma Firms Can Prepare for a GMP Inspection
Barbara W. Unger
June 30, 2021